Evidence map›Paper›PMID 36434103›Full record

ArticleSchizophrenia (Heidelberg, Germany)2022

Effects of Toxoplasma gondii infection on cognition, symptoms, and response to digital cognitive training in schizophrenia.

Anna Luiza Guimarães, David Richer Araujo Coelho, Linda Scoriels, Juliana Mambrini, Lis Ribeiro do Valle Antonelli, Priscilla Henriques, Andréa Teixeira-Carvalho, Olindo Assis Martins Filho, José Mineo, Lilian Bahia-Oliveira and 1 more

Erratum issuedAbstract read
In one paragraph

Article in Schizophrenia (Heidelberg, Germany), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Extracellular vesicles and circulating nucleic acids · 2026
    Article
  3. Beyond Latency: ChronicBiomedicines · 2025
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Anna Luiza Guimarães *Instituto de Psiquiatria, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.ORCID http://orcid.org/0000-0002-3785-5956
David Richer Araujo Coelho *Departamento de Imunoparasitologia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Linda ScorielsInstituto de Psiquiatria, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.ORCID http://orcid.org/0000-0001-6767-0189
Juliana MambriniInstituto René Rachou, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.
Lis Ribeiro do Valle AntonelliInstituto René Rachou, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.
Priscilla HenriquesInstituto René Rachou, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.
Andréa Teixeira-CarvalhoInstituto René Rachou, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.
Olindo Assis Martins FilhoInstituto René Rachou, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.
José MineoUniversidade Federal de Uberlândia, Uberlândia, Brazil.
Lilian Bahia-OliveiraDepartamento de Imunoparasitologia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.ORCID http://orcid.org/0000-0003-3001-8079
Rogério PanizzuttiInstituto de Psiquiatria, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil. rogerio.panizzutti@ipub.ufrj.br.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Studies indicate that neuroscience-informed digital cognitive training can remediate cognitive impairments in schizophrenia, but the factors contributing to these deficits and response to treatment remain unclear. Toxoplasma gondii is a neuroinvasive parasite linked to cognitive decline that also presents a higher prevalence in schizophrenia. Here, we compared the cognition and symptom severity of IgG seropositive (TOXO+; n = 25) and seronegative (TOXO-; n = 35) patients who participated in a randomized controlled trial of digital cognitive training. At baseline, TOXO+ subjects presented lower global cognition than TOXO- (F = 3.78, p = 0.05). Specifically, TOXO+ subjects showed worse verbal memory and learning (F = 4.48, p = 0.03), social cognition (F = 5.71, p = 0.02), and higher antibody concentrations were associated with increased negative (r = 0.42, p = 0.04) and total (r = 0.40, p = 0.04) schizophrenia symptoms. After training, the TOXO+ group showed higher adherence to the intervention (X

Identifiers

PMID36434103
PMCPMC9700796

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.